WINDLAS BIOTECH share price has zoomed 6% and is presently trading at Rs 1,093.1.
Meanwhile, the BSE HEALTHCARE index is at 43,665.5 (up 2.0%).
Among the top gainers in the BSE HEALTHCARE index today are SUN PHARMA ADV. RES. (up 7.6%) and CAPLIN POINT (up 4.5%).
FDC (down 0.9%) and MAX HEALTHCARE INSTITUTE (down 0.3%) are among the top losers today.
Over the last one year, WINDLAS BIOTECH has moved up from Rs 424.2 to Rs 1,093.1, registering a gain of Rs 668.9 (up 157.7%).
On the other hand, the BSE HEALTHCARE index has moved up from 29,654.9 to 43,665.5, registering a gain of 47.2% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 186.6%), SUVEN PHARMACEUTICALS (up 99.2%) and Glenmark Pharma (up 98.2%).
Get savings of Rs 6,050: Join our small cap research service today!
The BSE Sensex is at 79,802.8 (up 1.0%).
The top gainers among the BSE Sensex today are Bharti Airtel (up 4.4%) and Sun Pharma (up 2.9%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,123.7 (up 0.9%). Bharti Airtel and Sun Pharma are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,174.2 to 79,802.8, registering a gain of 13,628.6 points (up 20.6%).
WINDLAS BIOTECH net profit grew 11.6% YoY to Rs 157 million for the quarter ended September 2024, compared to a profit of Rs 140 million a year ago. Net sales rose 22.5% to Rs 1,870 million during the period as against Rs 1,527 million in July-September 2023.
For the year ended March 2024, WINDLAS BIOTECH reported 36.5% increase in net profit to Rs 582 million compared to net profit of Rs 426 million during FY23. Revenue of the company grew 23.0% to Rs 6,310 million during FY24.
The current Price to earnings ratio of WINDLAS BIOTECH, based on rolling 12 month earnings, stands at 37.3.
Equitymaster requests your view! Post a comment on "WINDLAS BIOTECH Gains 6%; BSE HEALTHCARE Index Up 2.0%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!